In today’s episode, we discuss drug launch prices and how they are impacted by the way that Medicare reimburses providers for them. My guest is Professor David Ridley, faculty director for Health Sector Management at Duke University’s Fuqua School of Business. He was the lead author of a paper that proposed the priority review voucher program, which became law in 2007 and created a market of over one billion dollars for drug development for neglected diseases.More information and the references for this show can be found here.WebsiteEmail: unbiased.est@gmail.comTwitter: @UnbiasedEstPod The Unbiased Estimator is a production of the Duke Med Econ Interest Group.  Host @DanWangMed. Co-host and Mixed by @iAnkitChoudhury. Music by Coma-Media from Pixabay.